This article is sponsored content brought to you by Biopharm Australia.
Biopharm Australia pioneered the veterinary development of sodium pentosan polysulfate as a disease modifying osteoarthritis drug (DMOAD) under the well-known name CARTROPHEN VET.
We are a world leader in osteoarthritis treatment with high standard of safety and efficacy. Our products are acknowledged internationally, being approved as veterinary medicines by regulatory authorities around the world in more than 22 countries, where other disease modifying osteoarthritis drug have failed to obtain registration.
Biopharm heavily invests in the development of new technologies and employee training. Recently three of members of staff Íde Kennedy, Conor Nolan and Vivek Bewley completed a course in Pharmaceutical and Medical Devices. David Cullis-Hill, the Managing Director, also completed a Masters in pharmaceutical manufacturing technology.
Recently we build a state of the art microbiological testing facility. This will allow us to perform all microbiological tests involved in the manufacturing of CVI and CEF in house. This will mean a faster turnaround time and a greater reliability on the results. Some of the tests we will be carrying out are Total Aerobic Microbial Counts, Total Yeast & Mould Counts, Pharmaceutical Waters, Bioburden Integrity Testing and Sterility Testing. The testing will be conducted according to British, European and US pharmacopoeias.
For more information
Call: 02 9389 0000
Email: email@example.com or firstname.lastname@example.org or visit www.cartrophen.com
Visit Biopharm Australia.